Two eukaryotic human prolactin (hPRL) expression vectors, based on a selectable dihydrofolate reductase (dhfr) marker, were used to transfect dhfr − Chinesehamster ovary (CHO) cells. One vector, p658-hPRL, contains the hepatitis-B virus-X cDNA coding for a viral transactivator and sequences mediating dhfr mRNA degradation. The other, pEDdc-hPRL, carries the encephalomyocarditis virus leader sequence coupled to hPRL cDNA to provide high-level protein expression, possibly via a mechanism of internal translation initiation in dicistronic mRNA. Without methotrexate (MTX) amplification, p658-hPRL-transfected stable cell lines, secreting up to $ 10 µg of hPRL/10 6 cells per day, could be rapidly obtained; production by pEDdc-hPRLtransfected cells was about 10-fold lower. However, a three-step MTX amplification of the latter led to clones secreting up to $ 30 µg of hPRL/10 6 cells per day. A pilot production using a hollow-fibre bioreactor indicated that highly concentrated hormone levels in the medium could be obtained, with a production of up to 150 µg of hPRL/ml per day. SDS/PAGE analysis indicated that recombinant hPRL contained $ 10 % glycosylated PRL. Chromatographically purified non-glycosylated and glycosylated recombinant hPRL had bioactivities of 35 and 16 i.u./mg, respectively (Nb2 cell bioassay). This appears to be the first report describing production and purification of recombinant hPRL from CHO cells, secreted at levels higher than reported thus far in eukaryotic systems.
Introduction
Human prolactin (hPRL), a protein hormone primarily secreted by the anterior pituitary, has a remarkably wide spectrum of biological activities [1] . Whereas PRL is best known for its stimulation of lactation, and growth and development of the mammary gland [2] , it has also been shown to mediate a variety of physiological processes, including growth and maturation of oocytes [3] , immune modulation [4] and osmoregulation [5] . Basically a singlechain protein with a molecular mass of 23 000 Da and three intramolecular disulphide bridges, PRL shows significant molecular polymorphism, including a varying percentage of the glycosylated form, which could underlie its diverse properties [1] . Quite a number of disorders in the area of pituitary function and reproduction have been linked to abnormal levels of PRL in the peripheral blood, making it one of the most frequently determined hormones in clinical laboratory assays [6] .
Although routine therapeutic applications of hPRL have not been established, recent studies indicate possible applications of this hormone in the treatment of women presenting with poor lactation associated with temporary pituitary ischaemia [7, 8] and in the restoration of normal sperm characteristics in hypoprolactinaemic, infertile men [9] . Administration of PRL also appears to be potentially useful for the treatment of infections and immunosuppression. Thus as recently found with experimental mice, PRL has a protective effect against pathogen-induced infections [10] , can restore haemorrhagic effects [11] and may be clinically useful in reversing myelosuppression induced by azidothymidine or in other myeloablative therapies [12] . Furthermore, recent in vitro studies have shown that recombinant hPRL (rec-hPRL) can reverse the antiproliferative effects of transforming growth factor β, indicating its potential application as an immunotherapeutic agent in cases of HIV infection [13] . In view of the above, an increasing need for rec-hPRL can be anticipated.
In the production of hPRL, recombinant DNA technology has been utilized as an attractive alternative to laborious pituitary gland extractions. Several laboratories have reported cytoplasmic expression of rec-hPRL in Escherichia coli in the form of inclusion bodies [14] [15] [16] [17] . However, recombinant proteins in inclusion bodies are present in a reduced and denatured state, and their solubilization and renaturation usually render low yields of biologically active protein and substantial contamination by partly aggregated and immunologically altered proteins [18, 19] . To circumvent such problems, our previous research was directed towards the production of rec-hPRL in a ' native ' form, as secreted into the periplasmic space of E. coli. Whereas our first product was linked to an N-terminal peptide tag [20] , more recently, secreted bacterially produced rec-hPRL was obtained in the authentic form, although at relatively low expression levels [6] .
The production of secreted rec-hPRL by eukaryotic and, in particular, by mammalian cells, is of major interest since such cells have a potential for secreting the hormone at high levels. Importantly, mammalian-cell-produced hPRL would, in contrast to bacterially produced hPRL, more closely resemble native pituitary hPRL, as it exhibits glycosylated and possibly other post-translationally modified forms. Glycosylated forms of hPRL appear to be of fundamental importance for physiological studies and for potential clinical applications. So far, only two research groups have reported expression of glycosylated (G) and non-glycosylated (NG) rec-hPRL in mammalian cells. Hirooka et al. [21] compared the secretion kinetics of G-hPRL and NG-hPRL produced by three transfected cell lines [COS-1, GH3 and Chinese-hamster ovary (CHO) cells] without, however, addressing the levels of expression of the hormone or a purification process. Price et al. [22] , utilizing a system based on murine cell line C127, obtained a 97 %-purified product. However, recombinant glycosylated human proteins produced by C127 cells have a carbohydrate structure which differs significantly from that of the natural counterparts ; it appears that, with regard to proper glycosylation, the CHO cell expression system is superior [23, 24] .
The presence of unusual sugar chains in a glycoprotein can be critical with regard to pharmaceutical applications, especially as they can affect the pharmacokinetics of the protein and the antigenicity of the carbohydrate moiety ; changes in the latter could provoke an immune response secondarily directed at the native molecule [25, 26] . The absence of antibody development as a reaction to chronic administration of CHO-cell-derived erythropoietin [24, 27] is an important consideration in favour of the use of CHO cells for recombinant protein production. Indeed, the CHO cell line has emerged as the vehicle of first choice for synthesis of therapeutic human glycoproteins [24, 28, 29] . It has been used successfully by several groups for the generation of glycoproteins showing great similarity to the natural products [23, 26, 27, 30] and with extremely high yields, reaching values up to 110 µg\10 6 cells per day of the recombinant product [25, [31] [32] [33] [34] [35] [36] .
In the present study we constructed two expression vectors for the synthesis and secretion by mammalian cells of hPRL as it occurs naturally, i.e. in both non-glycosylated and glycosylated forms. Both expression vectors are based on a dihydrofolate reductase (dhfr) gene marker linked to hPRL cDNA, but differ in expression-enhancement mechanisms. The vectors were evaluated with regard to (i) the ease with which stably transfected, highly productive rec-hPRLsecreting CHO cell lines could be obtained and (ii) the production of secreted rec-hPRL as affected by a productionenhancing treatment with methotrexate (MTX). A first approach to the purification and characterization of recombinant CHO-cell-produced G-hPRL and NG-hPRL is described, as is the potential development of a 22-kDa hPRL by-product.
Materials and methods

Construction of expression vectors
hPRL cDNA was obtained from pBluescript SK + -hPRL cDNA after partial EcoRI digestion [20] . The dicistronic mRNA expression vector pEDdc-hPRL was derived from pEDdc [37] , kindly provided by Dr C. R. Wood (Genetics Institute, Cambridge, MA, U.S.A.) by inserting the hPRL coding sequence into the single EcoRI site. The physical map is shown in Figure 1 (A). The correct insertion and orientation of the hPRL sequence in the construct were confirmed by restriction mapping.
The expression vector p658-hPRL was derived by replacing the interleukin 2 cDNA present in p7055 [35] with hPRL cDNA. The latter, obtained by PCR utilizing pEDdc-hPRL as a template, was inserted between the HindIII and BamHI sites. The physical map is shown in Figure  1 (B). The correct hPRL cDNA was confirmed by DNA sequencing.
The expression vector pEDdc-hPRL carries the encephalomyocarditis virus leader sequence inserted upstream of the selectable gene, which should provide a high level of expression of cDNA inserts in mammalian cells, possibly via a mechanism of internal translation initiation. The vector p658-hPRL contains the complete hepatitis-B virus-X gene coding for a viral transactivator and a sequence derived from the 3h-untranslated region of the granulocyte\ macrophage colony-stimulating factor that mediates selective dhfr mRNA degradation.
Vector transfection and expression
CHO dhfr − cells (clone DUKX-B11) have been described by Urlaub and Chasin [38] . Cells were maintained in minimal essential medium (MEM ; Gibco-BRL, Gaithersburg, MD, U.S.A.) supplemented with 1 % (v\v) anti-PPLO (pleuropneumonia-like organism) agent, 50 units\ml penicillin, 50 µg\ml streptomycin, 20 µg\ml gentamycin and 1.25 µg\ml fungizone (MEM+antibiotics) and 5 % fetal bovine serum (FBS ; Gibco-BRL). Transfection was carried out by Figure 1 Maps of vectors pEDdc-hPRL and p658-hPRL (A) pEDdc-hPRL, a pUC18 derivative, contains the simian virus 40 (SV40) origin of replication and enhancer element, the adenovirus major late promoter (MLP), the tripartite leader from adenovirus late mRNA (TPL) and a hybrid intron composed of the 5h splice site from the first leader of adenovirus major late mRNAs and a 3h splice site from an immunoglobulin gene (IVS). The hPRL cDNA is followed by the 5h untranslated leader from encephalomyocarditis (EMC) virus, a murine DHFR-coding region, the simian-virus-40 (SV40) late polyadenylation signal (SV 40-pA) and the adenovirus VAI RNA gene (VA) [37] . (B) p658-hPRL, a pML2 derivative, contains, downstream from the SV40 early enhancer-promoter (P SV40), the 5h untranslated region from human T-cell lymphotropic virus type I (HTLV1) and a synthetic intron containing the splice sites of the distal intron of the mouse α-globin gene (α-globin). The hPRL cDNA is followed by the late polyadenylation site of SV40 (SV40). Together with this expression unit, it contains a selection unit derived from the pSV2-dhfr vector coding for murine dhfr, including a sequence of the 3h granulocyte/macrophage colony-stimulating factor (GM-CSF) untranslated region and an SV40 intron followed by the SV40 polyadenylation site. Upstream from P SV40, the complete hepatitis-B virus-X gene (HBV-X), coding for a viral transactivator, is also present [35] .
the calcium phosphate precipitation technique [39] for both vectors and, 2 days post-transfection, cells were seeded into 20 100-mm culture dishes at 5i10 5 cells\dish, using α-MEM with L-glutamine and without ribonucleosides and deoxyribonucleosides, supplemented with 10 % dialysed FBS and 10 µg\ml ciprofloxacine (Bayer, Leverkusen, Germany) as selective medium. After 2 weeks, the transformed colonies were isolated using cloning cylinders and, following several subculture steps, the clones were analysed for PRL secretion. The most productive clones derived from pEDdc-hPRL transfection were further submitted to amplification using serial treatments with 20, 50 and 100 nM MTX in the same α-MEM medium supplemented with 10 % dialysed FBS.
To generate conditioned medium for rec-hPRL isolation and purification, pEDdc-hPRL-transfected CHO cells were grown on 100-mm culture dishes in α-MEM, containing antibiotics and 100 nM MTX, and supplemented with 10 % (v\v) dialysed FBS, until 40-50 % confluence was reached. The culture medium was then changed to the above medium from which serum had been omitted, and conditioned medium was harvested every 24 h until confluence was reached and stored at k80 mC. Alternatively, transfected CHO cells were seeded at a density of (1-3)i10 7 cells into the extracapillary space ($ 7 ml) of a cellulose cartridge (4-kDa molecular-mass cut-off) in a Cellmax Quad hollow-fibre bioreactor (Spectrum, Laguna Hills, CA, U.S.A.). As intracapillary media, α-MEM, containing antibiotics and 100 nM MTX and supplemented with 3 mg of glucose\ml, or a lowprotein, serum-free medium, CHO-S-SFM II (Gibco-BRL), containing antibiotics and 100 nM MTX, were used. Identical media, but supplemented with 10 % (v\v) FBS, were used in the extracapillary space. The cells were allowed to settle and adhere to the capillaries for 3 days, after which the extracapillary medium was replaced with fresh medium to remove unattached cells and debris. The perfusion medium was replaced periodically when its glucose concentration decreased to 2 mg\ml. After about 10 days, the extracapillary medium was replaced with serum-free medium and then harvested daily and stored at k80 mC. All incubations were carried out at 37 mC in a humidified incubator under 5% CO 2 .
Radio-immunoassay of hPRL
The amount of secreted hPRL was determined using a commercially available prolactin-immunoradiometric assay (Immunotech, Marseille, France) or by a double-antibody liquid-phase radio-immunoassay using reagents prepared at IPEN-CNEN (Sa4 o Paulo, Brazil) as described previously [20] . NIDDK-hPRL-RP-1 and NIDDK-anti-hPRL-3 were kindly provided by Dr A. F. Parlow from the National Hormone and Pituitary Program (Torrance, CA, U.S.A.). Humanblood-based immunoassay quality controls (Dade2 Tri-level, Baxter Diagnostic, Deerfield, IL, U.S.A.) were used for each standard curve.
Gel electrophoresis and Western-blot analysis
Discontinuous SDS\PAGE using 12 % polyacrylamide gels was performed as described by Laemmli [40] under nonreducing conditions, obtained by eliminating 2-mercaptoethanol from the sample buffer. Proteins were revealed by silver staining. Western-blot analysis was performed using 125 I-labelled Protein A [6] .
Amino acid sequence determination
The N-terminal amino acid sequences of the band corresponding to hPRL and of the lower molecular-mass form were determined using an Applied Biosystems model 476 A sequencer, as described in [6] .
PRL purification
Rec-hPRL present in conditioned culture medium was purified using a modified version of the method described by Price et al. [22] . A two-step purification process was used : the sample, adjusted to pH 5.0, was first applied to a sulphopropyl-(SP-) Sepharose Fast Flow column (Pharmacia, Sa4 o Paulo, Brazil) and eluted as described [22] . Briefly, hPRLcontaining medium was diluted with distilled water to a conductivity of less than 4.0 ms\cm at 4 mC and the pH was adjusted to 5.0 using acetic acid. The material was then applied on to the SP-Sepharose Fast Flow columm equilibrated in 50 mM sodium acetate (pH 5.0) and 0.01 % Tween 80 ; UV absorbance was monitored at 280 nm. After washing with the same buffer, the column was washed with 50 mM sodium acetate (pH 5.0), 90 mM NaCl and 0.01 % Tween 80. Prolactin was eluted from the column with 25 mM Hepes (pH 8.0) and 0.01 % Tween 80. The hPRL-containing eluate was then applied on to a Sephacryl S-100 gel-filtration column (Pharmacia) and eluted with 0.05 M ammonium bicarbonate, pH 8.0.
Separation of recombinant G-hPRL and NG-hPRL
Sephacryl S-100 eluate containing rec-hPRL was dialysed overnight at 4 mC against 50 mM sodium acetate (pH 5.0)\2 µM pepstatin A (Sigma, St. Louis, MO, U.S.A.), adjusted to 25 % ethylene glycol\5 % n-butanol and applied to a high-performance SP-Sepharose column equilibrated with 50 mM sodium acetate (pH 5.0), 5 % ethylene glycol and 5 % n-butanol (form purification buffer, FPB) [22] . After washing the column with FPB containing 200 mM NaCl, G-hPRL was eluted from the column with FPB containing 300 mM NaCl. NG-hPRL was subsequently eluted using 25 mM tricine buffer (pH 8.5), 5 % ethylene glycol and 5 % n-butanol.
Glycosidase digestion of G-hPRL
Purified G-hPRL, obtained by the method described above, was subjected to peptide N-glycosidase F treatment to confirm the presence of sugar chains. A sample of 400 ng of purified G-hPRL was boiled for 5 min in 20 µl of denaturing buffer (0.05 M sodium phosphate, pH 7.2\0.05 % SDS\0.5 % β-mercaptoethanol\0.5 % Nonidet P-40). Following addition of PMSF (up to 25 mM) and of 0.2 units of peptide Nglycosidase F (Sigma), the mixture was incubated overnight at 37 mC and then subjected to SDS\PAGE followed by silver staining. After demonstrating that the protein preparation had obtained an electrophoretic mobility coinciding with that of NG-hPRL (23 kDa) and was reconfirmed by Western-blot analysis to represent hPRL, the preparation of G-hPRL was used as an internal reference in SDS\PAGE analyses.
In vitro bioassay
The mitogenic activities of recombinant G-hPRL and NG-hPRL were determined using the Nb2 lymphoma cell-proliferation assay, as described previously [20] . The 3rd International Standard of hPRL (WHO 84\500 ; 53 m-i.u.\2.5 µg) was used as a reference preparation.
Results
The levels of rec-hPRL secretion by CHO cell lines transfected with the p658-hPRL or pEDdc-hPRL vectors are presented in Table 1 . While the best-producing clones of the p658-hPRL-transformed cells (n l 17) reached secretion levels of up to 8-10 µg\10 6 cells per day, all pEDdc-hPRLtransformed clones (n l 24) secreted less than 1 µg\10 6 cells per day. Two of the latter clones were subjected to treatment with MTX to obtain amplification of the dhfr gene marker. After a 3-step incubation with increasing concentrations of MTX, i.e. 20, 50 and 100 nM, cell lines were obtained from clone numbers 5 and 18 which showed, on average, 35-and 57-fold increases in rec-hPRL secretion relative to the two parent clones, respectively. In fact, the MTX-stimulated cell lines showed a hPRL secretion level which was about 3-fold higher than that obtained with the most productive p658-hPRL-transformed clones under nonstimulating conditions (Table 2) . A similar MTX treatment carried out on two p658-hPRL-transformed clones (numbers 5 and 16) did not significantly increase hPRL secretion levels (results not shown).
The percentage of glycosylated PRL in mixtures of GhPRL and NG-hPRL, secreted by pEDdc-hPRL-transfected CHO cells, was estimated. As illustrated in Figure 2 , various dilutions of a sample of culture medium, conditioned by CHO cells in 100-mm culture dishes, were subjected to electrophoresis. Following silver staining of the resolved proteins, the bands corresponding to G-hPRL (25 kDa) and NG-hPRL (23 kDa) were scanned densitometrically for assessment of the G-hPRL fraction. Glycosidase digestion of the 25-kDa band and Western blotting confirmed that it was due to G-hPRL (results not shown). The relationship between the amounts of NG-hPRL measured and the sample dilutions applied was quite linear, showing a correlation coefficient of r l 0.987 (P 0.01) for this particular example. The mean percentage of G-hPRL, as estimated from nine independent determinations carried out with seven different conditioned culture media, was 10.3 % (coefficient of variation, CV l 19.2 %). Figure 3 shows a typical example of analysis by SDS\PAGE of various steps of the purification of recombinant G-hPRL and NG-hPRL, including the partial separation obtained between G-hPRL and NG-hPRL on Sephacryl S-100 and the almost complete purification of either form by high-performance SP-Sepharose. The total recovery of rec-hPRL (G-hPRL+NG-hPRL), obtained after the second chromatographic step, amounted to 86 %, as determined by SDS\PAGE densitometry, while the final yields of G-hPRL and NG-hPRL were 3 and 18 %, respectively. The purity of the two preparations, as determined by scanning densitometry, was 99.5 % for NG-hPRL and 95 % for G-hPRL. The analysis was significantly enhanced by the use of the internal reference preparation of recombinant G-hPRL.
The biological (i.e. mitogenic) activities of purified, CHO-cell-produced G-hPRL and NG-hPRL were determined using the Nb2 lymphoma cell in vitro bioassay for lactogenic hormones and, as a reference compound, the International Standard of hPRL, WHO 84\500 (specific activity 21.2 i.u.\mg). The growth responses of the Nb2 lymphoma cell cultures to the three hormones are presented in Figure 4 . Results from three independent bioassays showed that the CHO-cell-produced NG-hPRL had a specific activity of 34.7 i.u.\mg (CV l 24.1 %), whereas the G-hPRL had a specific activity of 16.5 i.u.\mg (CV l 32.5 %).
Since the production of rec-hPRL in 100-mm culture dishes was in the order of only 5-6 µg\ml per day, preliminary experiments were carried out aimed at boosting the hormone production. To this end, transfected CHO cells were cultured in the extracellular space (capacity, 7 ml) of a hollow-fibre bioreactor, in low-protein, serum-free 
medium (CHO-S-SFM II)
. Under these conditions it was possible to substantially increase the rec-hPRL production, i.e. to 150 µg\ml per day. However, as shown in Figure 5(A) , the increase in the production of the hormone obtained under these conditions was associated with the formation of by-products, in particular lower-molecular-mass proteins associated with the isolation of both G-hPRL and NG-hPRL, leading to the formation of double bands. Western-blot analysis demonstrated that these lower-molecular-mass forms, together with other higher-molecular-mass compounds, were derivatives of hPRL ( Figure 5B ). Amino acid analysis of the N-terminal end of the lower-molecular-mass forms established the sequence Cys-Gln-Val-Thr-Leu-Arg, indicating that they were truncated forms of hPRL lacking the first ten N-terminal amino acid residues, and possibly represented hPRL fragments in both the glycosylated ($ 24 kDa) and non-glycosylated ($ 22 kDa) forms. Nterminal amino acid analysis also indicated that the main product indeed represented hPRL.
To investigate the formation of truncated hPRL, extracapillary fractions were collected at various times, following seeding of the CHO cells in the bioreactor, for SDS\PAGE and Western-blot analysis ; the intracapillary medium was not changed during the course of the experiment. As shown in Figure 6 , the truncated hPRL was not produced until after about 3 days of culturing, but it then increased rapidly, becoming the predominant form after 7 days. In other experiments, intracapillary medium changes were found to lead to a significant decrease in the production of this form (results not shown). It is notable that the truncated hPRL form was not observed when conventional dishes were used to cultivate the same strain of cells in identical culture medium ( Figures 5A and 5B, lanes 2) . It is likely, therefore, that the formation of the truncated hPRL is related to the much higher cell density, elevated hPRL concentrations, and possibly increased concentrations of cell-lysis-produced protease, present in the bioreactor as distinct from the petri dishes.
Discussion
High-level synthesis of rec-hPRL was for the first time obtained in CHO cells following their transfection with p658-hPRL and pEDdc-hPRL, two selectable dhfr marker expression vectors featuring different selection mechanisms (Figure 1 ). The principal feature of the p658-hPRL is to provide rapid generation of highly productive, rec-hPRLsecreting cell lines in a one-step procedure. The construction of the pEDdc-hPRL, a dicistronic expression vector comprising an internal ribosome entry site, is aimed at providing an even higher expression of the hormone. However, enhanced performance of the pEDdc-hPRL vector depends on the successful application of the MTX-based geneamplification procedure that is often quite tedious and time consuming. The expected performances of the two vectors were confirmed experimentally and, in both cases, the secretion of rec-hPRL obtained was the highest ever reported for this protein in a mammalian cell system (Tables  1 and 2 ). We are aware of only three reports addressing the production of rec-PRL in mammalian cells, two concerning hPRL [21, 22] and one concerning baboon and monkey PRLs [41] . The first two accounts do not provide any data with regard to rec-hPRL expression or secretion levels ; the third one reports expression of simian PRL by murine C127 cell lines ranging from 1 to 2 µg\ml per day, as judged by radioimmunoassay [41] . In comparing expression levels of recombinant proteins by different cell lines, cell productivity (e.g. µg\cell per day) appears to provide a better parameter than protein concentration. However, the figure quoted suggests that the simian PRL is expressed at a lower level than the rec-hPRL in the present CHO cell system.
It is widely accepted that recombinant human glycoproteins, synthesized by CHO cells, have carbohydrate structures that are quite similar to those of the native hormones [42] . In the present study, the percentage of GhPRL produced by the transfected CHO cell lines could be estimated quite accurately. All determinations were carried out using SDS\PAGE densitometry (Figure 2) , a method that circumvents the large, well-known bias introduced by methodologies based on the different immunoreactivities of NG-hPRL and G-hPRL. Furthermore, in performing the analysis directly on culture media, after a minimal number of operations, possible selective losses of the two hPRL forms during their purification were avoided. The percentage of rec-G-hPRL so established in the present study, i.e. 10.3 %, falls within the wide range reported for purified pituitaryderived hPRL [22, [43] [44] [45] , but is somewhat lower than that reported by Price et al. [22] for G-hPRL produced by murine C127 cells ($ 14 %) and that published by Hiraoka et al. [21] for CHO-cell-produced G-hPRL (17-18 %). The bioactivity of purified G-hPRL produced in our studies (16.5 i.u.\mg) was about half of that of NG-hPRL (34.7 i.u.\mg), as indicated by the Nb2 lymphoma cell bioassay (Figure 4 ). This value agrees with the bioactivity reported for pituitary GhPRL [43, 46] , but is higher than the bioactivity determined by Price et al. for G-hPRL secreted by C127 cells [22] . It may be noted, however, that most of these bioactivity data, including ours, are based on quantification of G-hPRL and NG-hPRL by immunological methods, a type of quantification that is greatly biased and in need of re-evaluation [44] .
The pilot production of rec-hPRL in a hollow-fibre bioreactor led to a substantial increase ($ 30-fold) in the concentration of the hormone when compared with its production in culture dishes. Whereas the bioreactor promises to be extremely useful for future application in rechPRL production, the development of hPRL-derived contaminants during its use ( Figure 5 ) needs further addressing. Of interest is a major form of these by-products, i.e. the truncated hPRL of about 22 kDa lacking the first 10 Nterminal amino acid residues and tentatively identified as hPRL (Figure 6 ). An analogous form, whose N-terminus also begins with a cysteine at position 11, was first described by Cole et al. [41] as a by-product in the bioreactor production of simian PRL. The development of this derivative was attributed to proteolytic cleavage, which may even have occurred during the purification of the hormone. Shelikoff et al. [47] described the appearance of clipped forms of NGhPRL and G-hPRL obtained in T-flask culture of the mouse C127 cell line, the same cell line that, transfected with hPRL cDNA, was utilized by Genzyme for rec-hPRL production [22] . Since these authors found that the formation of this clipped form was inhibited by the presence of PMSF, they suggested that it could result from the action of an extracellular serine protease whose cleavage site is Arg10\Cys-11 [47] . In our case, we demonstrated that the truncated hPRL forms, probably identical to those described by Shelikoff et al. [47] , develop in large quantities in the culture medium of the bioreactor (Figure 6 ). It appears likely that the development of such byproducts in the bioreactor may be prevented, or at least reduced, by appropriate changes in the experimental conditions and by the addition of PMSF.
Although the truncated hPRL form appeared as an undesired by-product in the production of rec-hPRL, it may have merits of its own. Due to the loss of the N-terminal disulphide bond it is likely to have substantially reduced bioactivity in the Nb2 cell bioassay [48] . Interestingly, it has been shown that loss of the N-terminal disulphide bond in rat PRL, as a result of Cys-4 Ser mutagenesis, profoundly increased the rate by which the hormone was secreted by transfected pituitary cell lines, suggesting that the N-terminal disulphide loop may play a role in the intracellular transit and storage of PRL [49] . Further work, aimed at a more comprehensive characterization of the truncated hPRL observed in the present study, is in progress.
In conclusion, transfection of CHO cells with hPRL expression vectors has led to high-level secretion of bioactive rec-hPRL, in both the glycosylated and nonglycosylated forms. Changes in the experimental conditions aimed at improving the production and purity of the rechPRL generated in a bioreactor are currently being investigated.
